Amgen, Cytokinetics And Servier Announce Topline Results From GALACTIC-HF, A Phase 3 Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
– Trial Met Primary Composite Endpoint of Reduction in Cardiovascular Death or Heart Failure Events – Trial Did Not Meet